Form 4: KALA BIO Director Gregory D. Perry Acquires Shares and Options

Director Gregory D. Perry reported the acquisition of common stock and stock options in KALA BIO, Inc. through a grant of restricted stock units and a stock option award.

Summary

• On June 11, 2024, Gregory D. Perry, a director of KALA BIO, Inc., acquired 1,400 shares of common stock through a grant of restricted stock units (RSUs) and was granted a stock option to purchase 3,150 shares.
• The RSUs vest on the earlier of June 11, 2025, or the date of the first annual meeting following June 11, 2024, subject to continued service.
• The stock option, with an exercise price of $6.18, also vests on the earlier of June 11, 2025, or the date of the first annual meeting following June 11, 2024, and expires on June 10, 2034.
• Following these transactions, Perry directly owns 3,150 derivative securities and beneficially owns 10,894 shares of common stock, including 8,525 unvested RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices and aligns director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule, contingent on continued service, incentivizes the director to remain with the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies to align management and director interests with shareholders. The grants are part of the company's equity incentive plan.

Comparison to Industry Standards

• Equity grants to directors are a standard practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• Vesting schedules tied to continued service are also common, ensuring that directors remain committed to the company's long-term success.
• The size of the grant is typical for a director-level position in a company of KALA BIO's size and stage of development.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the equity grants as a positive sign, indicating that the company values its leadership.

Key Dates